Metabolic syndrome is characterized by a clustering of cardiovascular and metabolic risk factors. This syndrome is now widely recognized as a distinct pathologic entity. It is receiving a great deal of attention in the medical literature and also in the lay press. People with metabolic syndrome have a clustering of the following risk factors, including detrimental changes in glucose tolerance and insulin resistance, abdominal (visceral) obesity, atherogenic dyslipidemia, and hypertension. Metabolic syndrome is associated with important cardiovascular and cerebrovascular and metabolic risks. Prevention and treatment are therefore of great importance. Preventive measures involving lifestyle are mandatory. In addition, metabolic syndrome patients will require pharmacologic treatment, usually for the rest of their lives. Complex patterns of drug treatment are required. This review provides an extensive and critical review of the drug treatment of this complex pathologic entity.
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109:433-438.
3.
Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based Treatment of Metabolic Syndrome / van Zwieten, Mancia 213 on interactions between obesity, diabetes, and inflammation. Metabolic syndrome. Circulation. 2005;111: 1448-1454.
4.
Pedrinelli R, Dell’Olmo G, Penno G, et al. Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. J Hypertens. 2003;21:1163-1169.
5.
Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
6.
Isomaa B. A major health hazard: the metabolic syndrome. Life Sci. 2003;73:2395-2411.
7.
Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004;14:686-695.
8.
Kendall DM, Sobel BE, Coulson AM, et al. The insulin resistance syndrome and coronary artery disease. Coron Artery Disl. 2003;14:335-348.
9.
Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Int Med. 2004;164:1066-1076.
10.
Cuspidi C, Meani S, Fusi V, et al. Metabolic syndrome and target organ damage in untreated essential hypertension. J Hypertens. 2004;22:1991-1998.
11.
Egan BM, Julius S. Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome. Dialogues Cardiovasc Med. 2004;9:143-157.
12.
Grassi G, Seravalle G, Quarti Trevano F, Dell’Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension. 2003;42:873-877.
13.
Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560-563.
14.
Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68-72.
15.
Grassi G, Dell’Oro R, Facchini A, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22:2363-2369.
16.
Anderson EA, Balon TW, Hoffmann RP, et al. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension. 1992;19: 62-69.
17.
Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens. 1997;10:77-83.
18.
Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of the metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-556.
19.
De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease in Clinical Practice. Eur J Card Prev Rehab. 2003;10:S1-S78.
20.
Guidelines Committee. European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens. 2003;21: 1011-1053.
21.
Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9-14.
22.
Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs. 2003;63:1165-1184.
23.
Meijboom LJ. The endocannabinoid system: a new therapeutic target for multi-risk factor management. Neth Heart J. 2004;12(suppl)2:29-30.
24.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1-receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397.
Yki-Järvinen H. Thiazolidinediones. New Engl J Med. 2004;351:1106-1118.
27.
Kendale DM, Sobel BE, Coulston AM, et al. The insulin resistance syndrome and coronary artery disease. Coron Artery Disl. 2003;14:335-348.
28.
Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004;22:1453-1458.
29.
Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in the North of Sweden efficacy evaluation (ALPINE-study). J Hypertens. 2003;21:1563-1574.
30.
Schupp M, Janke J, Clasen R, Unger TH, Kintscher U. Angiotensin type I receptor blockers induce peroxisome proliferator-activated receptor--activity. Circulation. 2004;109:2054-2057.
31.
Ruilope LM, Segure J, Schiffrin E. ACE-inhibition of angiotensin receptor blockade: which should we use in diabetic patients?J Renin Angiotensin Aldosterone Sys. 2003;4:74-79.
32.
Low MR,Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis. BMJ. 2003;326:1423-1427.
33.
Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther. 2003;41:567-577.
34.
Pearson TA, Blair SM, Daniels SR, et al. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation.2002;106:388-391.
